-
Arbutus Biopharma Corporation NASDAQ:ABUS Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).
Location: 701 Veterans Circle, Pennsylvania, 18974, US | Website: arbutusbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
553.6M
Cash
127.8M
Avg Qtr Burn
-17.96M
Short % of Float
4.27%
Insider Ownership
22.22%
Institutional Own.
53.90%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Imdusiran +NA therapy +VTP-300 Details Hepatitis B | Phase 2a Data readout | |
Imdusiran +NA therapy +IFN Details Hepatitis B | Phase 2a Data readout | |
AB-101 Details Hepatitis B | Phase 1 Data readout | |
AB-836 (capsid inhibitor) Details Hepatitis B | Failed Discontinued | |
Failed Discontinued | ||
AB-161 (Oral RNA destabilizer) Details Hepatitis B | Failed Discontinued |